Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025

世界の主要なジェネリック医薬品メーカー分析

◆タイトル:Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025
◆商品コード:VGAIN5072207
◆調査・発行会社:visiongain
◆発行日:2015年7月
◆ページ数:231
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥271,649見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥452,849見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥754,849見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、世界の主要なジェネリック医薬品メーカーについて調査・分析し、以下の構成でお届けいたします。

・エグゼクティブサマリー
・ジェネリック医薬品市場の概観
・主要なジェネリック医薬品メーカー分析
・地域別メーカー分析:北米、ヨーロッパ、インド
・専門家の見解
・結論・提言

Generic Drug Producers – Discover Top Companies’ Revenue Prospects Now, Benefiting Your Influence
What does the future hold for manufacturers and sellers of generic medicines? Visiongain’s new report shows you leading companies’ prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.

For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?

Sales predictions and other data to help you stay ahead in competitive intelligence
In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.

Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.

Assessments of top companies – capabilities, results, competition and sales potentials
Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information:
• Discussion of activities, technologies and recent financial results
• Assessment of developments – mergers and acquisitions (M&A), new products, outlooks, challenges and plans
• Forecasting of generic drug revenues to 2025 (for 19 leading companies).

Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.

For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies’ gross profit margins, EBITDA margins and historical revenue growth.

The following sections show how our new investigation helps your work.

North America – outlooks for leading generic drug producers and sellers
First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms:
• Mylan
• Pfizer
• Abbott
• Hospira
• Apotex
• Par Pharmaceuticals.

In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.

Europe – prospects for leading generics players
Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms:
• Novartis (Sandoz)
• Actavis
• Sanofi
• Fresenius Kabi
• Pharmstandard
• Gedeon Richter
• Stada Arzneimittel.

The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.

India – analysis of leading generic drug firms
Our new work also assesses 10 Indian generic drug producers, including these firms:
• Sun Pharmaceutical Industries
• Dr. Reddy’s Laboratories
• Lupin
• Ranbaxy
• Aurobindo
• Glenmark
• Wockhardt.

How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.

Producers from the rest of world – assess technologies, progress and prospects
Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies:
• Teva Pharmaceutical Industries
• EMS
• Aspen Pharmacare
• Nichi-Iko
• Abdi Ibrahim
• Hypermarcas
• Eurofarma
• Sawai Pharmaceuticals.

【レポートの目次】

1. Report Overview
1.1 Introduction to this Survey
1.2 Main Report Findings
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Top 50 Generic Drug Manufacturers
2.1 Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2014
2.2 Top 50 Generic Drug Companies: Revenue Analysis, 2014
2.3 Top 50 Generic Drug Companies Regional Distribution, 2014
2.4 Report Coverage
2.5 Report Complexity
2.5.1 Obtaining Data from Private Companies
2.5.2 Financial Years Variability
2.5.3 Generics Revenue Identification
2.5.4 Defining Generics 1: Difference Between Biosimilars and Generics
2.5.5 Defining Generics 2: ‘Super-Generics’ and APIs
2.5.6 Defining Generics 3: Rx and OTC

3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2015-2025
3.1 Companies Covered in this Chapter
3.2 Leading US Generic Drug Manufacturers: Financial Performance Outline, 2014
3.3 Mylan: Number One US Manufacturer of Generic Drugs: Company Overview, 2015
3.3.1 Mylan Historical Performance and Financial Results Analysis, 2015
3.3.2 Mylan Generic Drugs Revenue Forecast, 2015-2025
3.3.3 First Class II Transdermal Approval Consolidates Mylan’s Top Status in the US Market
3.3.4 Tender System Hurts Mylan’s German Market Share but the Company Retains its Australian Dominance
3.3.5 Mylan’s Focus on Complex Generics: Reasons and Causes
3.3.6 Mylan’s Generic Portfolio Remains the Company’s Core Strength
3.3.7 Mylan’s Winning Acquisition Strategy
3.3.8 Mylan Acquired Abbott: Towards Scale Economies and Vertical Integration
3.3.9 Mylan’s Potential Acquisition Plans – Outlook
3.4 Pfizer – The Leading Research-Based Pharmaceutical: Company Overview, 2015
3.4.1 Pfizer Historical Performance and Financial Results Analysis, 2015
3.4.2 Pfizer Generic Drugs Revenue Forecast, 2015-2025
3.4.3 Pfizer Internationalization and Restructuring Strategy
3.4.4 Pfizer’s Acquisition of Hospira: A Solution for Boosting the Generic Revenue Stream?
3.4.5 Prospects for Pfizer’s Generic Drugs Business
3.5 Abbott: Company Overview, 2015
3.5.1 Abbott Business Segments Performance
3.5.2 Abbott Historical Performance and Financial Results Analysis, 2015
3.5.3 Abbott Generic Drugs Revenue Forecast, 2015-2025
3.5.4 Abbott’s Acquisitions: Overview and Analysis, 2010-2014
3.5.5 Abbott’s Sale of its Overseas Branded Generic Business: Implications
3.5.6 Future Prospects for Abbott Generic Drugs Business
3.6 Hospira: Company Overview, 2015
3.6.1 Integrated Infusion Therapies and Other Hospira Businesses
3.6.2 Hospira – Injectable Expert Among the Top 10 Generic Companies Acquired by Pfizer
3.7 Apotex: Company Overview, 2015
3.7.1 Apotex Expansion to Europe and Beyond
3.7.2 Apotex Drives Business Diversification Through R&D
3.8 Par Pharmaceuticals: Company Overview, 2015
3.8.1 Par Pharmaceuticals’ Acquisition of JPH Group Holdings
3.8.2 Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs
3.8.3 Buy Out of Indian Ethics Bio Lab Demonstrates Par’s Interest in Niche Products
3.9 Valeant Pharmaceuticals: Company Overview, 2015
3.9.1 Valeant: A Major Challenger in the Emerging Markets
3.9.2 Branded Generics are Crucial to Valeant’s Emerging Market Ambitions
3.9.3 Valeant Implements Acquisition Strategy to Boost Revenues
3.9.4 Valeant Generic Drugs Revenue Forecast, 2015-2025
3.10 Endo Pharmaceuticals: Company Overview, 2015
3.10.1 Endo: Pain Expertise in Branded and Generic Drugs
3.10.2 Endo’s Expansion on the South African Market
3.10.3 Performance Analysis on Endo’s Qualitest Business
3.10.4 Future Prospects for Endo Pharmaceuticals Generic Drugs Business
3.10.5 Endo Generic Drugs Revenue Forecast, 2015-2025
3.11 Pharmascience – Another Major Canadian Player: Company Overview, 2015
3.11.1 Over 200 Generic Product Families
3.11.2 Korean Venture Driving Diversification for Pharmascience
3.12 Mallinckrodt: Company Overview, 2015
3.12.1 Mallinckrodt Generics: Valuable Addition to the Company’s Portfolio
3.12.2 Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt’s Income
3.12.3 What is Mallinckrodt’s Advantage Against Strong Competition?
3.12.4 Partnerships and Acquisitions: Crucial for Mallinckrodt’s Rapid Expansion
3.13 Akorn Pharmaceuticals: Company Overview, 2015
3.13.1 Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach
3.13.2 Akorn Strengthens its Position on the US Ophthalmology Market
3.14 Alvogen – A Privately-Owned US Company is the One to Watch: Company Overview, 2015
3.14.1 Alvogen Unique Business Model Proves Good Results
3.14.2 Alvogen Target is to Become Top 10 Global Generic Player
3.15 Sagent Pharmaceuticals – One of the Fastest Growing Providers of Specialty Generics in the US: Company Overview, 2015
3.15.1 Will Sagent’s Different Business Model Achieve Growth?

4. Top European Generic Drug Manufacturers: Activities and Prospects, 2015-2025
4.1 Companies Covered in this Chapter
4.2 Leading European Generic Drug Manufacturers: Financial Performance Outline, 2014
4.3 CEE Markets Home to Many Big Generic Contenders
4.4 Novartis (Sandoz) – the World’s Second Largest Generic Pharmaceutical Company: Overview, 2015
4.4.1 Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2015
4.4.2 Novartis (Sandoz) Generic Drugs Revenue Forecast, 2015-2025
4.4.3 Novartis (Sandoz) Key Developments Analysis, 2015
4.4.4 Europe is the Main Market for Sandoz
4.4.5 Emphasis on Complex, Differentiated Generics and Biosimilars
4.4.6 Future Prospects for Novartis Generic Drugs Business
4.5 Actavis: Company Overview, 2015
4.5.1 Actavis Historical Performance and Financial Results Analysis, 2015
4.5.2 Actavis Generic Drugs Revenue Forecast, 2015-2025
4.5.3 Implications of Actavis Large Product Portfolio
4.5.4 Actavis Customized Commercial Model for International Markets
4.5.5 Merger Creates New Force in the Generic Drug Industry
4.5.6 Actavis Acquisition of Forest Laboratories: Move Towards Specialty Pharmaceuticals
4.5.7 The Acquisition of Auden McKenzie Will Add More than 150 Products to Actavis Product Line
4.5.8 Actavis Acquired Allergan with Aim to be a Top 10 Pharmaceutical Company
4.6 Sanofi: Company Overview, 2015
4.6.1 Sanofi Historical Performance and Financial Results Analysis, 2015
4.6.2 Sanofi Generic Drugs Revenue Forecast, 2015-2025
4.6.3 Adaptive Business Model for Sanofi’s Generic Drug Division
4.6.4 Zentiva Benefits from Strong Presence in the EU Market
4.6.5 Future Prospects for Sanofi Generics
4.7 Fresenius Kabi – Leading Generic Intravenous Drug Player: Company Overview, 2015
4.7.1 Intra Venous Drugs: The Main Product Line for Fresenius Kabi
4.7.2 Fresenius Kabi Will Continue to Expand
4.8 Pharmstandard – The Biggest Russian Pharmaceutical Manufacturer: Company Overview, 2015
4.8.1 Acquisitions Strengthen Pharmstandard Manufacturing and Product Base
4.8.2 Pharmstandard Benefits from Strong Organic Production Capacity
4.8.3 Future Prospects for Pharmstandard Generic Drugs Business
4.8.4 Pharmstandard Generic Drugs Revenue Forecast, 2015-2025
4.9 Gedeon Richter – Hungarian Leader Looking Further Afield: Company Overview, 2015
4.9.1 Female Health and Fertility Segments Form Core Strengths for Gedeon Richter
4.9.2 Specialisation Strategy for Further Growth
4.9.3 A Pan-European Pharmaceutical Presence for the Future?
4.9.4 Gedeon Richter Generic Drugs Revenue Forecast, 2015-2025
4.10 Krka – Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2015
4.10.1 Prescription Generics: Krka’s Major Focus
4.10.2 Russia is the Largest National Market for Krka, but for How Long?
4.10.3 Krka Generic Drugs Revenue Forecast, 2015-2025
4.11 Stada Arzneimittel – Major Presence in Germany and Central Europe: Company Overview, 2015
4.11.1 Negative Effect from the CIS Region Crisis
4.11.2 Strong Product Development with Over 600 Product Launches in 2014
4.11.3 Stada Targets the Biosimilar Sector with Promising Deals
4.11.4 Stada Arzneimittel Generic Drugs Revenue Forecast, 2015-2025
4.12 Perrigo: Company Overview, 2015
4.12.1 Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself?
4.12.2 Rx Pharmaceuticals: Main Contributors to Perrigo’s Revenue Stream
4.13 Polpharma – Poland’s Generic Powerhouse: Company Overview, 2015
4.13.1 Polpharma’s Continuous Product Portfolio Enlargement
4.13.2 Strong Regional Presence in Poland, Russia and Kazakhstan
4.13.3 Acquisition Increases Polpharma Dominance in the Polish Market

5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2015-2025
5.1 Companies Covered in This Chapter
5.2 India: Generics Supplier to the World
5.3 Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2014
5.4 Sun Pharmaceutical – Leader in the Indian Generic Drug Market, Company Overview, 2015
5.4.1 Sun Has a Leading Presence in the Generic Export Market
5.4.2 Mega Acquisitions to Enlarge Sun’s Operations?
5.4.3 Sun Pharmaceutical Generic Drugs Revenue Forecast, 2015-2025
5.5 Dr. Reddy’s Laboratories: Company Overview, 2015
5.5.1 At the Forefront of the Indian Generic Boom: Dr. Reddy’s Revenue Exceeded $2bn in 2014
5.5.2 North America and Russia are the Largest Export Markets for Dr. Reddy’s
5.5.3 Alliance with GlaxoSmithKline
5.5.4 Dr. Reddy’s Early Leadership in Biosimilar Antibodies
5.5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast, 2015-2025
5.6 Lupin – The Most Successful Indian Generic Firm in the US Market: Company Overview, 2015
5.6.1 Lupin’s Continuous Portfolio Growth and Focus on Complex Injectables
5.6.2 Strong R&D Investment in New Delivery Systems and Original Products
5.6.3 Lupin Generic Drugs Revenue Forecast, 2015-2025
5.7 Cipla – Mumbai Based Generic Giant: Company Overview, 2015
5.7.1 Generic Copaxone: A Major Product Launch for Cipla
5.7.2 Cipla’s Leadership in Anti-Retroviral Drugs and Focus on Key Markets
5.7.3 Chronic Disease: A Significant Target for Cipla
5.7.4 Cipla Generic Drugs Revenue Forecast, 2015-2025
5.8 Ranbaxy -The Second Largest Indian Generic Manufacturer with Sales in 150+ Countries: Company Overview, 2015
5.8.1 Dermatological Therapeutics: Targeted Area of Growth for Ranbaxy
5.8.2 ANDA Applications Giving Promising Opportunities
5.8.3 High Income Stream from the Emerging Markets
5.8.4 Merger with Sun
5.9 Aurobindo – The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2015
5.9.1 High-Margin Specialty Generics
5.9.2 ANDA Filings and Approvals by Region, 2014
5.9.3 CRAMS Opportunities
5.10 Glenmark – Specialty Company Still Leveraging Generic Growth: Overview, 2015
5.10.1 Generics Remain Part of Global Growth Strategy for Glenmark
5.10.2 Glenmark Benefits from Africa and Middle East Exports Boom
5.10.3 Glenmark Generic Drugs Revenue Forecast, 2015-2025
5.11 Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2015
5.11.1 US Market Growth in 2014
5.11.2 Biosimilars, Novel Delivery Systems and Original Drugs will Drive Growth for Wockhardt
5.12 Cadila – Leader in Indian Cardiovascular Market: Company Overview, 2015
5.12.1 Biochem Acquisition Boosts Cadila’s Revenue
5.12.2 Increasing Presence in the US Market
5.12.3 Cadila: A Future Biosimilar Force?
5.13 Ipca Laboratories – One of Top 10 Indian Pharma Exporters: Company Overview, 2015
5.13.1 Fast Development Due to Niche Strategic Approach

6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2015-2025
6.1 Companies Covered in this Chapter
6.2 Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2014
6.3 Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market
6.4 Teva Pharmaceutical Industries: Company Overview of the World’s Generic Industry Leader, 2015
6.4.1 Teva Historical Performance and Financial Results Analysis, 2010-2014
6.4.2 Teva Generic Drugs Revenue Forecast, 2015-2025
6.4.3 Teva’s Global Presence
6.4.4 How did Teva Achieve its Success?
6.4.5 Teva Operational Strategy: Focus on Cost Reduction
6.4.6 The US Market Stagnates but Teva Sustains its Strong Penetration
6.4.7 From Volume to Value Driven Strategy in the European Markets
6.4.8 Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma
6.4.9 Will Mylan Eventually Join Teva’s Long Acquisition List?
6.4.10 Future Prospects for Teva Generic Drugs Business
6.5 EMS – Leading the South American Generic Market: Company Overview, 2015
6.5.1 First Brazilian Company to Export Generics to Europe
6.5.2 EMS Has the Most Advanced Latin American R&D Base
6.6 Aspen Pharmacare – South African Giant Continues to Expand: Company Overview, 2015
6.6.1 Ten-Year CAGR to 2014 Exceeds 25%
6.6.2 Philippines Added to Areas of Activity
6.6.3 Continuing Over 30% Dominance in South Africa Generic Market
6.6.4 Asia-Pacific and International Business Main Revenue Contributors in 2014
6.6.5 Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen
6.6.6 Aspen Generic Drugs Revenue Forecast, 2015-2025
6.7 Nichi-Iko: Company Overview, 2015
6.7.1 More Than 900 Generic Products in Nichi-Iko Portfolio
6.7.2 Nichi-Iko Venture with Sanofi Complements Strategy
6.8 Abdi Ibrahim: Turkey’s Leading Pharmaceutical Company
6.8.1 Large Product Portfolio Helps to Sustain Market Position
6.8.2 Abdi Ibrahim has a Vast International Scope
6.9 Hypermarcas SA – Brazilian Pharmaceutical and OTC Giant: Company Overview, 2015
6.9.1 Price Increase and High Profit Margins: Would they be Sustainable?
6.10 Eurofarma – Rapidly-Growing Generics Power in Brazil: Company Overview, 2015
6.10.1 Eight Diversified Business Divisions
6.10.2 M&A Extending Latin American Reach for Eurofarma
6.11 Taro Pharmaceuticals – The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2015
6.11.1 FDA Corticosteroid Spray Approval Boosts Taro’s Portfolio in 2014
6.12 Towa Pharmaceuticals – Another Big Japanese Player: Company Overview, 2015
6.12.1 Large Number of Generic Products in Towa’s Portfolio
6.12.2 Towa’s Broad and Expanding Production Capacity
6.13 Sawai Pharmaceuticals – Osaka-Based Generic Leader: Company Overview, 2015
6.13.1 Annual manufacturing Capacity of 10bn Tablets
6.13.2 Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai
6.13.3 M&A Boosts Sawai’s R&D

7. Interviews from Our Survey
7.1 Interview with Jean-Marie Arnaud, Senior Vice President and Head of Sanofi Generics
7.1.1 Sanofi Generics Act with the Expertise of Sanofi Group
7.1.2 Sanofi Uses Innovative and Adapted Business Model Worldwide
7.1.3 Increasing Revenues for Sanofi Generics as the Company Continues to Focus on Emerging Markets and Portfolio Enlargement
7.1.4 A Generic Product is no Longer Just a Pure Copy of an Original
7.1.5 The Usage of Generic Medicines in Europe Can Still be Optimised
7.1.6 A Combination of Strategies Proves Successful in the Generics Industry
7.2 Interview with a Representative of the Generic Pharmaceutical Association (GPhA)
7.2.1 86% of all Prescriptions in the US are for Generic Drugs
7.2.2 Patent Settlements Provide Higher Savings and Early Market Entry for Generics
7.2.3 The Cost Burden will Increase if the Generic Drug Labelling Rule Changes
7.2.4 Biosimilars – the New Target for Generic Drug Manufacturers

8. Conclusions
8.1 Companies’ Growth Strategies
8.2 Why are Big Pharma Companies Targeting Generics?
8.3 Watson and Actavis Merger: The First Major Consolidation for the Generic Drug Industry
8.4 The Changing Dynamics of the Generic Drug Companies
8.5 Big Pharma Business Models Evolve
8.6 Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies
8.7 Complex Generics with High Entry Barriers Continue to Increase in Importance
8.8 Future Trends for Generic Drug Producers – What’s Possible?

List of Tables
Table 1.1 Currency Exchange Rates to $US
Table 2.1 Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 1-25, 2014
Table 2.2 Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 26-50, 2014
Table 2.3 Top 50 Generic Drug Manufacturers: Revenue ($m) and Market Share (%) According to Group Rank, 2014
Table 2.4 Regional Distribution of the Top 50 Companies, 2014
Table 3.1 Top 10 North American Generic Drug Manufacturers: Revenues ($m) and Ranking, 2014
Table 3.2 Mylan: Company Overview, 2015
Table 3.3 Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Table 3.4 Mylan: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 3.5 Pfizer: Company Overview, 2015
Table 3.6 Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Table 3.7 Pfizer: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 3.8 Abbott: Company Overview, 2015
Table 3.9 Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Table 3.10 Abbott: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 3.11 Hospira: Company Overview, 2015
Table 3.12 Apotex: Company Overview, 2015
Table 3.13 Par Pharmaceutical: Company Overview, 2015
Table 3.14 Valeant Pharmaceuticals: Company Overview, 2015
Table 3.15 Valeant: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 3.16 Endo Pharmaceuticals: Company Overview, 2015
Table 3.17 Endo: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 3.18 Pharmascience: Company Overview, 2015
Table 3.19 Mallinckrodt: Company Overview, 2015
Table 3.20 Akorn Pharmaceuticals: Company Overview, 2015
Table 3.21 Alvogen: Company Overview, 2015
Table 3.22 Sagent Pharmaceuticals: Company Overview, 2015
Table 4.1 Top 10 European Generic Manufacturers: Revenues ($m) and Ranking, 2014
Table 4.2 Novartis (Sandoz): Company Overview, 2015
Table 4.3 Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Table 4.4 Novartis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.5 Actavis: Company Overview, 2015
Table 4.6 Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014
Table 4.7 Actavis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.8 Sanofi: Company Overview, 2015
Table 4.9 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Table 4.10 Sanofi: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.11 Fresenius Kabi: Company Overview, 2015
Table 4.12 Pharmstandard: Company Overview, 2015
Table 4.13 Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.14 Gedeon Richter: Company Overview, 2015
Table 4.15 Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.16 Krka: Company Overview, 2015
Table 4.17 Krka: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.18 Stada: Company Overview, 2015
Table 4.19 Stada: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 4.20 Perrigo: Company Overview, 2015
Table 4.21 Polpharma: Company Overview, 2015
Table 5.1 Top 10 Indian Generic Manufacturers: Revenues ($m) and Ranking, 2014
Table 5.2 Sun Pharmaceutical: Company Overview, 2015
Table 5.3 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 5.4 Dr. Reddy’s: Company Overview, 2015
Table 5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 5.6 Lupin: Company Overview, 2015
Table 5.7 Lupin: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 5.8 Cipla: Company Overview, 2015
Table 5.9 Cipla: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 5.10 Ranbaxy: Company Overview, 2015
Table 5.11 Ranbaxy: ANDA Filings and Approvals by Region, 2014
Table 5.12 Aurobindo: Company Overview, 2015
Table 5.13 Aurobindo: ANDAs Filings and Approvals by Region, 2014
Table 5.14 Glenmark: Company Overview, 2015
Table 5.15 Glenmark: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 5.16 Wockhardt: Company Overview, 2015
Table 5.17 Cadila: Company Overview, 2015
Table 5.18 Ipca: Company Overview, 2015
Table 6.1Top 10 Rest of the World Generic Drug Manufacturers, Revenues ($m) and Ranking, 2014
Table 6.2 Teva: Company Overview, 2015
Table 6.3 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Table 6.4 Teva: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 6.5 Teva: Revenue Breakdown (%) by Region, 2014
Table 6.6 Teva: New Generic Drugs Launches by Region, 2014
Table 6.7 Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014
Table 6.8 EMS: Company Overview, 2015
Table 6.9 Aspen: Company Overview, 2015
Table 6.10 Aspen: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
Table 6.11 Nichi-Iko: Company Overview, 2015
Table 6.12 Abdi Ibrahim: Company Overview, 2015
Table 6.13 Hypermarcas: Company Overview, 2015
Table 6.14 Eurofarma: Company Overview, 2015
Table 6.15 Taro Pharmaceutical: Company Overview, 2015
Table 6.16 Towa Pharmaceutical: Company Overview, 2015
Table 6.17 Sawai Pharmaceutical: Company Overview, 2015

List of Figures
Figure 2.1 Top 50 Generic Drug Manufacturers: Revenues ($m), 2014
Figure 2.2 Generic Drug Manufacturers: Revenue ($m) Comparison by Group Rank, 2014
Figure 2.3 Top 50 Generic Drug Manufacturers: Market Share (%) Amongst the Top 50 Companies According to Group Rank, 2014
Figure 2.4 Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2014
Figure 2.5 Regional Balance Among the Top 50 Generic Drug Manufacturers, 2014
Figure 2.6 Biosimilars and Generics: Overview, 2015
Figure 3.1 Top 10 North American Generic Drug Manufacturers: Revenues ($m), 2014
Figure 3.2 Leading North American Generic Drug Manufacturers: Gross Profit Margin (%), 2014
Figure 3.3 Leading North American Generic Drug Manufacturers: EBITDA Margin (%), 2014
Figure 3.4 Leading North American Generic Drug Manufacturers: Revenue Growth (%), 2013-2014
Figure 3.5 Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Figure 3.6 Mylan: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 3.7 Mylan: Number of Generic Products on Leading European Markets, 2014
Figure 3.8 Mylan: Revenue Breakdown (%) by Business Segment, 2014
Figure 3.9 Mylan: Revenue Breakdown (%) by Therapeutic Area, 2014
Figure 3.10 Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Figure 3.11 Pfizer: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 3.12 Abbott: Revenue Breakdown (%) by Business Segment, 2014
Figure 3.13 Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
Figure 3.14 Abbott: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 3.15 Valeant: Revenue Breakdown (%) by Business Segment, 2014
Figure 3.16 Valeant: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 3.17 Endo: Revenue Breakdown (%) by Business Segment, 2014
Figure 3.18 Endo: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 3.19 Akorn’s Major Acquisition: Overview of the Reasons, 2015
Figure 4.1 Top 10 European Generic Manufacturers: Revenues ($m), 2014
Figure 4.2 Leading European Generic Drug Manufacturers: Gross Profit Margin (%), 2014
Figure 4.3 Leading European Generic Drug Manufacturers: EBITDA Margin (%), 2014
Figure 4.4 Leading European Generic Drug Manufacturers: AGR (%), 2013-2014
Figure 4.5 Novartis: Revenue Breakdown by Business Segment, 2014
Figure 4.6 Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Figure 4.7 Novartis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.8 Sandoz: Revenue Breakdown by Region, 2014
Figure 4.9 Sandoz: Revenue Breakdown by Business Segment, 2014
Figure 4.10 Actavis Sales Breakdown (%), 2014
Figure 4.11 Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014
Figure 4.12 Actavis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.13 Actavis Sales Breakdown (%), 2014
Figure 4.14 Sanofi: Generic Drugs Revenue Breakdown by Region, 2014
Figure 4.15 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Figure 4.16 Sanofi: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.17 Pharmstandard: Revenue Breakdown by Business Segment, 2014
Figure 4.18 Pharmstandard: Export Sales Breakdown by Country, 2014
Figure 4.19 Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.20 Gedeon Richter: Revenue Breakdown by Therapeutic Segment, 2014
Figure 4.21 Gedeon Richter: Revenue Breakdown by Country, 2014
Figure 4.22 Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.23 Krka: Revenue Breakdown by Business Segment, 2014
Figure 4.24 Krka: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.25 Stada: Revenue Breakdown (%) by Business Segment, 2014
Figure 4.26 Stada: Revenue Breakdown by Region, 2014
Figure 4.27 Stada: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 4.28 Perrigo Company: Revenue Breakdown by Business Segment, 2014
Figure 5.1 Top 10 Indian Generic Manufacturers: Revenues ($m), 2014
Figure 5.2 Top 10 Indian Generic Drug Manufacturers: Gross Profit Margin (%), 2014
Figure 5.3 Top 10 Indian Generic Drug Manufacturers: EBITDA Margin (%), 2014
Figure 5.4 Top 10 Indian Generic Drug Manufacturers: Revenue AGR (%), 2013-2014
Figure 5.5 Sun Pharmaceutical: Revenue Breakdown (%) by Business Segment, 2014
Figure 5.6 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 5.7 Dr. Reddy’s: Revenue Breakdown (%) by Business Segment, 2014
Figure 5.8 Dr. Reddy’s: Revenue Breakdown (%) by Region, 2014
Figure 5.9 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 5.10 Lupin: Revenue Breakdown (%) by Markets, 2014
Figure 5.11 Lupin: Revenue Breakdown (%) by Therapeutic Area, 2014
Figure 5.12 Lupin: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 5.13 Cipla: Revenue Breakdown (%) by Region, 2014
Figure 5.14 Cipla: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 5.15 Ranbaxy: Revenue Breakdown (%) by Markets, 2014
Figure 5.16 Glenmark: Sales Revenue Increase (%) by Region, 2013-2014
Figure 5.17 Glenmark: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 5.18 Wockhardt: Revenue Breakdown (%) by Region, 2014
Figure 5.19 Ipca: Revenue Breakdown (%) by Therapeutic Area, 2014
Figure 6.1 Top 10 Rest of the World Generic Manufacturers: Revenues ($m), 2014
Figure 6.2 Leading Rest of the World Generic Drug Manufacturers: Gross Profit Margin (%), 2014
Figure 6.3 Leading Rest of the World Generic Drug Manufacturers: EBITDA Margin (%), 2014
Figure 6.4 Leading Rest of the World Generic Drug Manufacturers: AGR (%), 2013-2014
Figure 6.5 Teva: Revenue Breakdown (%) by Business Segment, 2014
Figure 6.6 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
Figure 6.7 Teva: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 6.8 Teva: Revenue Breakdown by Region, 2014
Figure 6.9 Teva: New Generic Drug Launches by Region, 2014
Figure 6.10 Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014
Figure 6.11 Aspen: Revenue Breakdown (%) by Region, 2013 and 2014
Figure 6.12 Aspen: Revenue Increase (%) by Region, 2014
Figure 6.13 Aspen: European Revenue Breakdown (%) by Region, 2014
Figure 6.14 Aspen: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
Figure 6.15 Taro Pharmaceutical: Revenue Breakdown (%) by Region, 2014

【レポートのキーワード】

ジェネリック医薬品メーカー、製薬

★調査レポート[世界の主要なジェネリック医薬品メーカー分析] ( Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025 / VGAIN5072207) 販売に関する免責事項
[世界の主要なジェネリック医薬品メーカー分析] ( Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025 / VGAIN5072207) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆